377 related articles for article (PubMed ID: 18391486)
1. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Ohbayashi T
Dement Geriatr Cogn Disord; 2008; 25(5):399-407. PubMed ID: 18391486
[TBL] [Abstract][Full Text] [Related]
2. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
5. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
[TBL] [Abstract][Full Text] [Related]
6. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
Homma A; Atarashi H; Kubota N; Nakai K; Takase T
J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
[TBL] [Abstract][Full Text] [Related]
9. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
Cummings J; Jones R; Wilkinson D; Lopez O; Gauthier S; Waldemar G; Zhang R; Xu Y; Sun Y; Richardson S; Mackell J
J Alzheimers Dis; 2010; 21(3):843-51. PubMed ID: 20634594
[TBL] [Abstract][Full Text] [Related]
10. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
13. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.
Seltzer B; Zolnouni P; Nunez M; Goldman R; Kumar D; Ieni J; Richardson S;
Arch Neurol; 2004 Dec; 61(12):1852-6. PubMed ID: 15596605
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
[TBL] [Abstract][Full Text] [Related]
16. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials.
Winblad B; Black SE; Homma A; Schwam EM; Moline M; Xu Y; Perdomo CA; Swartz J; Albert K
Curr Med Res Opin; 2009 Nov; 25(11):2577-87. PubMed ID: 19735164
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
18. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
Wattmo C; Hansson O; Wallin AK; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2008; 26(3):203-11. PubMed ID: 18769065
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
[TBL] [Abstract][Full Text] [Related]
20. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease.
Hashimoto M; Yatabe Y; Kaneda K; Honda K; Ikeda M
Psychogeriatrics; 2009 Dec; 9(4):196-203. PubMed ID: 20377821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
